, Volume 67, Issue 11, pp 1521–1530 | Cite as

Proton-Pump Inhibitor Therapy in Patients with Gastro-Oesophageal Reflux Disease

Putative Mechanisms of Failure
Current Opinion


Proton-pump inhibitor (PPI) failure in gastro-oesophageal reflux disease (GORD) patients has become the main reason for referral of these patients to gastroenterology specialists. It is estimated that 30% of GORD patients requiring a PPI once daily will experience treatment failure. Patients with non-erosive reflux disease are the most common GORD-related group in which once-daily PPI therapy fails. Various mechanisms have been suggested to underlie PPI failure in GORD patients. The most pertinent include weakly acidic reflux, duodenogastro-oesophageal reflux, visceral hyperalgesia, delayed gastric emptying, psychological co-morbidity and concomitant functional bowel disorders, as well as others. Because of the importance of PPI failure as a target for future drug development, further understanding of the most relevant underlying mechanisms is needed.


  1. 1.
    Locke GR 3rd, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997 May; 112(5): 1448–56PubMedCrossRefGoogle Scholar
  2. 2.
    Inadomi JM, McIntyre L, Bernard L, et al. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completed relieved with PPIs. Am J Gastroenterol 2003; 98(9): 1940–4PubMedCrossRefGoogle Scholar
  3. 3.
    Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of 56 treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998; 10(2): 119–24CrossRefGoogle Scholar
  4. 4.
    Fass R, Shapiro M, Dekel R, et al. Proton pump inhibitor failure in reflux disease: where next? Aliment Pharmacol Ther 2005; 22(2): 79–94PubMedCrossRefGoogle Scholar
  5. 5.
    Vaezi MF. ‘Refractory GERD’: acid, nonacid, or not GERD? Am J Gastroenterol 2004; 99(6): 989–90PubMedCrossRefGoogle Scholar
  6. 6.
    Richter JE, Bochenek W. Pantoprazole US GERD Study Group. Oral pantoprazole for erosive esophagitis: a placebo-controlled randomized clinical trial. Am J Gastroenterol 2000; 95(11): 3071–80Google Scholar
  7. 7.
    Johnson DA, Lauritsen K, Junghard O, et al. Evaluation of symptoms is an unreliable predictor of relapse of erosive esophagitis in patients receiving maintenance PPI therapy [abstract no. T1646]. Gastroenterology 2003; 124 (4 Suppl.): A540CrossRefGoogle Scholar
  8. 8.
    Fass R, Thomas S, Traxler D, et al. Patient reported outcome of heartburn improvement: doubling the proton pump inhibitor (PPI) dose in patient who failed standard dose PPI versus switching to a different PPI [abstract no. 326]. Gastroenterology 2004; 146 (4 Suppl. 2): A37Google Scholar
  9. 9.
    Fass R, Murthy U, Hayden CW, et al. Omeprazole 40mg once a day is equally effective as lansoprazole 30mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy: a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000; 14(12): 1595–603PubMedCrossRefGoogle Scholar
  10. 10.
    Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2(8): 656–64PubMedCrossRefGoogle Scholar
  11. 11.
    Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32(10): 974–9PubMedCrossRefGoogle Scholar
  12. 12.
    Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002; 51(6): 885–92CrossRefGoogle Scholar
  13. 13.
    Bardhan KD, Hawkey CJ, Long RG, et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. Aliment Pharmacol Ther 1995; 9(2): 145–51CrossRefGoogle Scholar
  14. 14.
    Castell DO, Richter JE, Robinson R, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 1996; 91(9): 1749–57Google Scholar
  15. 15.
    Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther 2001; 15(2): 227–31PubMedCrossRefGoogle Scholar
  16. 16.
    Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared to omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96(3): 656–65PubMedCrossRefGoogle Scholar
  17. 17.
    Cooper BT, Neumann CS, Cox MA, et al. Continuous treatment with omeprazole 20mg daily for up to 6 years in Barrett’s oesophagus. Aliment Pharmacol Ther 1998; 12(9): 893–7PubMedCrossRefGoogle Scholar
  18. 18.
    Fass R, Sampliner RE, Malagon IB, et al. Failure of oesophageal acid control in candidates for Barrett’s oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther 2000; 14(5): 597–602PubMedCrossRefGoogle Scholar
  19. 19.
    Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett’s esophagus. Am J Gastroenterol 1994; 89(10): 1844–8PubMedGoogle Scholar
  20. 20.
    Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett’s esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996; 44(6): 700–5PubMedCrossRefGoogle Scholar
  21. 21.
    Gallup Study of Consumers’ use of Stomach Relief Products. Princeton (NJ): The Gallup Organization, 2000Google Scholar
  22. 22.
    Vela M, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120(7): 1599–606PubMedCrossRefGoogle Scholar
  23. 23.
    Bredenoord A, Weusten B, Curvers W, et al. Determinants of perception of heartburn and regurgitation. Gut 2006; 55: 313–8PubMedCrossRefGoogle Scholar
  24. 24.
    Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006 Oct; 55(10): 1398–402PubMedCrossRefGoogle Scholar
  25. 25.
    Frazzoni M, De Micheli E, Zentilin P, et al. Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther 2004; 20(1): 81–8PubMedCrossRefGoogle Scholar
  26. 26.
    Martinez SD, Malagon IB, Garewal HS, et al. Non-erosive reflux disease (NERD): acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17(4): 537–45PubMedCrossRefGoogle Scholar
  27. 27.
    Watson RG, Tham TC, Johnston BT, et al. Double blind crossover placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux: the “sensitive oesophagus”. Gut 1997; 40(5): 587–90PubMedGoogle Scholar
  28. 28.
    Fass R, Ofman JJ. Gastroesophageal reflux disease: should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97(8): 1901–9PubMedGoogle Scholar
  29. 29.
    Hobson AR, Matthews P, Furlong P, et al. The role of esophageal afferent pathway sensitivity in non-erosive reflux disease [abstract no. 128]. Gastroenterology 2004; 126 (4 Suppl. 2): A18CrossRefGoogle Scholar
  30. 30.
    Shapiro M, Green C, Bautista J, et al. Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid. Am J Gastroenterol 2006 May; 101(5): 1084–91PubMedCrossRefGoogle Scholar
  31. 31.
    Vaezi MF. Duodenogastroesophageal reflux. In: Castro D, Richter J, editors. The oesophagus. Philadelphia (PA): Lippincott Williams & Wilkins, 2004: 1553–8Google Scholar
  32. 32.
    Netzer P, Gut A, Brundler R, et al. Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. Aliment Pharmacol Ther 2001; 15(9): 1375–84PubMedCrossRefGoogle Scholar
  33. 33.
    Marshall RE, Anggiansah A, Manifold DK, et al. Effect of omeprazole 20mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett’s oesophagus. Gut 1998; 43(5): 603–6PubMedCrossRefGoogle Scholar
  34. 34.
    Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett’s esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004; 99(6): 981–8PubMedCrossRefGoogle Scholar
  35. 35.
    Siddiqui A, Rodriguez-Stanley S, Zubaidi S, et al. Esophageal visceral sensitivity to bile salts in patients with functional heartburn and in healthy control subjects. Dig Dis Sci 2005; 50(1): 81–5PubMedCrossRefGoogle Scholar
  36. 36.
    Kudara N, Chiba T, Orii S, et al. Gastric emptying of patients with persistent reflux symptoms and erosive esophagitis under PPI therapy [abstract no 23]. Neurogastroenterol Motil 2004; 16(5): 654Google Scholar
  37. 37.
    Sotoudehmanesh R, Ali Asgari A, Ansari R, et al. Endoscopic findings in end-stage renal disease. Endoscopy 2003; 35(6): 502–5PubMedCrossRefGoogle Scholar
  38. 38.
    Cucchiara S, Minella R, Campanozzi A, et al. Effects of omeprazole on mechanisms of gastroesophageal reflux in childhood. Dig Dis Sci 1997; 42(2): 293–9PubMedCrossRefGoogle Scholar
  39. 39.
    Liacouras CA, Campbell C, Ruchelli E, et al. Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol 2005; 3: 1198–206PubMedCrossRefGoogle Scholar
  40. 40.
    Remedios M, Campbell C, Jones DM, et al. Eosinophilic esophagitis in adults: clinical, endoscopie, histologie findings, and response to treatment with fluticasone proprionate. Gastrointest Endosc 2006; 63: 3–12PubMedCrossRefGoogle Scholar
  41. 41.
    Straumann A, Spichtin H-P, Grize L, et al. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 2003; 125: 1660–9PubMedCrossRefGoogle Scholar
  42. 42.
    Croese J, Fairley SK, Masson JW, et al. Clinical and endoscopic features of eosinophilic esophagitis in adults. Gastrointest Endosc 2003; 58: 516–22PubMedCrossRefGoogle Scholar
  43. 43.
    Potter JW, Saeian K, Staff D, et al. Eosinophilic esophagitis in adults: an emerging problem with unique eseophageal features. Gastrointest Endosc 2004; 59: 355–61PubMedCrossRefGoogle Scholar
  44. 44.
    Zimmerman SL, Levine MS, Rubesin SE, et al. Idiopathic eosinophilic esophagitis in adults: the ringed esophagus. Radiology 2005; 236: 159–65PubMedCrossRefGoogle Scholar
  45. 45.
    Johnston BT, Lewis S, Collins J, et al. Acid perception in gastro-oesophageal reflux disease is dependent on psychosocial factors. Scand J Gastroenterol 1995; 30: 1–5PubMedCrossRefGoogle Scholar
  46. 46.
    Nojkov B, Chey W, Adlis S, et al. Predictors of response to PPI therapy in patients with GERD: the influence of co-morbid IBS and psychological disease [abstract]. Gastroenterology 2005; 128 (4 Suppl. 2): A61CrossRefGoogle Scholar
  47. 47.
    Delhotal-Landes B, Cournot A, Vermerie N, et al. The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drub Metab Pharmacokinet 1991; Spec No 3: 315–20Google Scholar
  48. 48.
    Dammann HG, Fuchs W, Richter G, et al. Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther 1997; 11(2): 359–64PubMedCrossRefGoogle Scholar
  49. 49.
    Leite L, Lambrecht N, Sachs G, et al. Is omeprazole resistance due to mutations of cysteine 813 or 822 in the acid pump? [abstract]. Gastroenterology 1995; 108: A147Google Scholar
  50. 50.
    Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002; 72(4): 453–60PubMedCrossRefGoogle Scholar
  51. 51.
    Kawamura M, Ohara S, Koike T, et al. The effect of lansoprazole on erosive reflux esophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 2003; 17: 965–73PubMedCrossRefGoogle Scholar
  52. 52.
    Egan LJ, Myhre GM, Mays DC, et al. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment Pharmacol Ther 2003; 17(12): 1521–8PubMedCrossRefGoogle Scholar
  53. 53.
    Peghini PL, Katz PO, Bracy NA, et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93(5): 763–7PubMedCrossRefGoogle Scholar
  54. 54.
    Ours TM, Fackler WK, Richter JE, et al. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003; 98(3): 545–50PubMedCrossRefGoogle Scholar
  55. 55.
    Fouad YM, Katz PO, Castell DO. Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther 1999; 13(11): 1467–71PubMedCrossRefGoogle Scholar
  56. 56.
    Nzeako UC, Murray JA. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Ther 2002; 16(7): 1309–16PubMedCrossRefGoogle Scholar
  57. 57.
    Orr WC, Harnish MJ. The efficacy of omeprazole twice daily with supplemental H2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity. Aliment Pharmacol Ther 2003; 17(12): 1553–8PubMedCrossRefGoogle Scholar
  58. 58.
    Verdu EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36(4): 539–43PubMedCrossRefGoogle Scholar
  59. 59.
    Vigneri S, Termini R, Savarino V, et al. Review article: is Helicobacter pylori status relevant to the management of GORD? Aliment Pharmacol Ther 2000; 14 Suppl. 3: 31–42PubMedCrossRefGoogle Scholar
  60. 60.
    Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117(1): 11–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Section of GastroenterologyThe Neuro-Enteric Clinical Research Group, Southern Arizona VA Health Care SystemTucsonUSA
  2. 2.University of Arizona Health Sciences CenterTucsonUSA

Personalised recommendations